← Back to Screener
Pfizer Inc. (PFE)
Price$27.52
Favorite Metrics
Price vs S&P 500 (26W)2.47%
Price vs S&P 500 (4W)-7.31%
Market Capitalization$156.69B
P/E Ratio (Annual)20.17x
Indicated Dividend Yield (Annual)6.24%
All Metrics
P/CF (Annual)13.39x
Book Value / Share (Quarterly)$15.21
P/TBV (Annual)4.32x
Indicated Dividend (Annual)$1.72
Revenue Growth (3Y)-14.80%
Cash Flow / Share (Quarterly)$1.60
Payout Ratio (TTM)98.75%
Price vs S&P 500 (YTD)6.54%
Gross Margin (TTM)75.81%
Net Profit Margin (TTM)12.42%
EPS (TTM)$1.36
10-Day Avg Trading Volume31.09M
EPS Excl Extra (TTM)$1.36
Revenue Growth (5Y)8.48%
EPS (Annual)$1.36
Dividend / Share (Annual)$1.72
ROI (Annual)5.14%
Gross Margin (Annual)75.81%
Net Profit Margin (5Y Avg)17.33%
Cash / Share (Quarterly)$2.39
P/E Basic Excl Extra (TTM)20.16x
Revenue Growth QoQ (YoY)-1.16%
EPS Growth (5Y)-3.51%
P/E Normalized (Annual)20.17x
ROA (Last FY)3.73%
Revenue Growth TTM (YoY)-1.64%
EBITD / Share (TTM)$2.55
ROE (5Y Avg)16.35%
Operating Margin (TTM)15.43%
Cash Flow / Share (Annual)$1.60
P/B Ratio1.81x
P/B Ratio (Quarterly)1.64x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.52x
Net Interest Coverage (TTM)4.52x
ROA (TTM)3.74%
EV / EBITDA (TTM)15.17x
EPS Incl Extra (Annual)$1.36
Current Ratio (Annual)1.16x
Quick Ratio (Quarterly)0.87x
3-Month Avg Trading Volume44.41M
52-Week Price Return25.05%
EV / Free Cash Flow (Annual)24.28x
P/E Incl Extra (TTM)20.16x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$5.76
P/S Ratio (Annual)2.50x
Asset Turnover (Annual)0.30x
52-Week High$28.75
Operating Margin (5Y Avg)18.86%
EPS Excl Extra (Annual)$1.36
CapEx CAGR (5Y)-1.19%
Tangible BV CAGR (5Y)-1.19%
26-Week Price Return11.22%
Quick Ratio (Annual)0.87x
13-Week Price Return7.74%
Total Debt / Equity (Annual)0.75x
Current Ratio (Quarterly)1.16x
Enterprise Value$220,338.77
Revenue / Share Growth (5Y)8.17%
Asset Turnover (TTM)0.30x
Book Value / Share Growth (5Y)6.01%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.41x
Pretax Margin (Annual)12.02%
Cash / Share (Annual)$2.39
3-Month Return Std Dev23.97%
Gross Margin (5Y Avg)69.76%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)6.42%
EBITDA Interim CAGR (5Y)-41.16%
ROE (Last FY)8.99%
Net Interest Coverage (Annual)4.52x
EPS Basic Excl Extra (Annual)$1.36
P/FCF (TTM)15.25x
Receivables Turnover (TTM)5.36x
EV / Free Cash Flow (TTM)24.28x
Total Debt / Equity (Quarterly)0.75x
EPS Incl Extra (TTM)$1.36
Receivables Turnover (Annual)5.36x
ROI (TTM)5.11%
Dividend Growth Rate (5Y)2.51%
P/S Ratio (TTM)2.50x
Pretax Margin (5Y Avg)18.13%
Revenue / Share (Annual)$10.95
Tangible BV / Share (Annual)$5.76
Forward P/E9.31x
Free OCF CAGR (5Y)-4.81%
Price vs S&P 500 (52W)-10.05%
P/E Ratio (TTM)20.16x
EPS Growth TTM (YoY)-3.46%
Year-to-Date Return10.68%
5-Day Price Return0.80%
EPS Normalized (Annual)$1.36
ROA (5Y Avg)7.29%
Net Profit Margin (Annual)12.42%
Month-to-Date Return-1.85%
Cash Flow / Share (TTM)$2.92
EBITD / Share (Annual)$2.54
EPS Growth (3Y)-37.13%
Operating Margin (Annual)15.43%
LT Debt / Equity (Annual)0.71x
P/CF (TTM)13.39x
ROI (5Y Avg)10.92%
P/E Excl Extra (TTM)20.16x
LT Debt / Equity (Quarterly)0.71x
EPS Basic Excl Extra (TTM)$1.36
P/TBV (Quarterly)4.32x
Payout Ratio (Annual)125.75%
P/B Ratio (Annual)1.64x
Dividend / Share (TTM)$1.72
Inventory Turnover (TTM)1.41x
Pretax Margin (TTM)12.02%
Book Value / Share (Annual)$15.21
Price vs S&P 500 (13W)4.88%
Net Margin Growth (5Y)-10.80%
Dividend Yield (TTM)6.24%
Beta0.34x
P/FCF (Annual)17.26x
Revenue / Share (TTM)$11.01
ROE (TTM)8.68%
52-Week Low$21.87
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.55
3.55
3.43
3.49
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share) | 1.40x | 69.14% | 72.55% | -8.08% | $47.99 |
About
Pfizer is among the world's largest pharmaceutical companies with approximately $60 billion in annual sales, primarily from prescription drugs and vaccines. Key revenue drivers include blockbuster therapies Prevnar 13, Vyndaqel, and Eliquis, with international markets—particularly emerging economies—accounting for 40% of total sales.